trending Market Intelligence /marketintelligence/en/news-insights/trending/ttcKuj2B94Odo0eM6zn70w2 content esgSubNav
In This List

Fitch affirms Allergan's ratings; outlook revised to positive

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Fitch affirms Allergan's ratings; outlook revised to positive

Fitch Ratings affirmed Allergan plc's ratings at BBB- and revised the outlook to positive from stable.

The rating agency said the positive outlook reflects the Botox-maker's strengthening credit metrics. Assuming generic competition for Allergan's eye drug Restasis becomes available in the market before 2019 ends, Fitch expects the company to operate with debt/EBITDA at or below 3.0x beginning 2020.

In addition, Fitch anticipates the Dublin-based pharmaceutical company will remain an active buyer in the M&A field with its steady free cash flow and existing cash balances available to buy targeted growth-oriented assets. The rating agency noted that Allergan's deals will be generally smaller compared to its earlier transactions and will be funded with internally generated liquidity to support a more stable debt leverage profile.

Fitch projects low- to mid-single-digit organic sales growth for Allergan during 2019 to 2020, excluding the negative impact of generic Restasis competition.